Prosthetic Antigen Receptors.

Prosthetic Antigen Receptors.
复制标题

假体抗原受体。

DOI:
10.1021/jacs.5b06166
复制
发表时间:
2015
影响因子:
15
通讯作者:
Wagner,CarstonR
Wagner,CarstonR
中科院分区:
化学1区
文献类型:
--
作者:
Shen,Jingjing;Vallera,DanielA;Wagner,CarstonR

文献摘要

参考文献

相似文献

嵌合抗原受体(汽车)已经显示出用于癌症的免疫治疗的巨大前景。然而,对患者T细胞进行基因工程改造的需求已经提出了重大的生产和安全挑战。为了解决这些问题,我们已经证明,化学自组装纳米环(CSAN)展示单链抗体可以结合到T细胞受体/CD 3复合物的CD 3 ε亚基和恶性B细胞(如B-白血病或淋巴瘤)上的CD 22抗原。我们证明了多价和双特异性形式允许抗CD 3/抗CD 22 CSAN稳定地结合T细胞表面超过4天,同时通过用FDA批准的无毒药物甲氧苄啶处理而容易地在细胞膜上分解。在CD 22 + Raji细胞存在的情况下,用抗CD 3/抗CD 22 CSAN修饰的T细胞显示出选择性上调白细胞介素-2(IL-2)和干扰素-γ(IFN-γ)的产生并启动细胞毒性。总之,我们的结果表明,抗CD 3/抗CD 22双特异性CSAN作为人工抗原受体提供了汽车的潜在替代方案。
Chimeric antigen receptors (CARs) have shown great promise for the immunological treatment of cancer. Nevertheless, the need to genetically engineer a patient’s T-cells has presented significant production and safety challenges. To address these issues, we have demonstrated that chemically self-assembled nanorings (CSANs) displaying single chain antibodies can bind to both the CD3 ε subunit of the T-cell-receptor/CD3 complex and the CD22 antigen on malignant B cells such as B-leukemias or lymphomas. We demonstrate that the multivalent and bispecific format allows the antiCD3/antiCD22 CSANs to stably bind to T-cell surfaces for greater than 4 days, while being easily disassembled on the cell membrane by treatment with the nontoxic FDA approved drug, trimethoprim. In the presence of CD22+ Raji cells, T-cells modified with antiCD3/antiCD22 CSANs were shown to selectively up-regulate the production of interleukin-2 (IL-2) and interferon-γ (IFN-γ) and to initiate cytotoxicity. Taken together, our results demonstrate that antiCD3/antiCD22 bispecific CSANs offer a potential alternative to CARs, as prosthetic antigen receptors.
DOI: 10.1021/ja107153a
发表时间: 2010-12-08
影响因子: 15
作者:
Li Q;So CR;Fegan A;Cody V;Sarikaya M;Vallera DA;Wagner CR
通讯作者: Wagner CR
DOI: 10.1056/nejmoa1103849
发表时间: 2011-08-25
期刊: The New England journal of medicine
影响因子: --
作者:
Porter DL;Levine BL;Kalos M;Bagg A;June CH
通讯作者: June CH
DOI: 10.1002/anie.200803507
发表时间: 2008-01-01
影响因子: 16.6
作者:
Li, Qing;Hapka, David;Wagner, Carston R.
通讯作者: Wagner, Carston R.
DOI: 10.1158/0008-5472.can-08-0461
发表时间: 2008-08-01
期刊: CANCER RESEARCH
影响因子: 11.2
作者:
Du, Xing;Beers, Richard;FitzGerald, David J.;Pastan, Ira
通讯作者: Pastan, Ira
DOI: 10.1021/mp300303k
发表时间: 2012-11-05
影响因子: 4.9
作者:
Fegan A;Kumarapperuma SC;Wagner CR
通讯作者: Wagner CR